contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


analyst-group-analyst-group-comment-on-pila-pharma-initiated-preclinical-studies-in-obesity

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

PILA PHARMA är ett kliniskt bioteknikbolag baserat i Malmö, Sverige. Bolaget utvecklar nya orala läkemedel för globalt vanliga metabola sjukdomar som diabetes, fetma och hjärt-kärlsjukdomar samt terapier för smärtbehandling. Bolaget har erhållit en särläkemedelsbeteckning i USA för den smärtsamma sällsynta sjukdomen Erythromelalgia. Bolaget är specialiserat på utveckling av farmaceutiska läkemedel baserade på TRPV1-antagonister.

PILA PHARMA

Pila Pharma AB (“Pila Pharma” or “the Company”) announced on 26 January that the Company’s preclinical studies in obesity have been completed. The studies showed that body weight in the obese...

<div class="mfn-preamble">Pila Pharma AB (“Pila Pharma” or “the Company”) announced on 26 January that the Company’s preclinical studies in obesity have been completed. The studies showed that body weight in the obese rats included in the study was not affected, however, the final results of the study are not yet complete, and it remains unknown whether the rats were exposed to Pila Pharma’s candidate XEN-D0501. In connection with the study outcome, Pila Pharma also announced that the Company has entered into an agreement with a new clinical contract research organization (CRO) to prepare and submit an application for a clinical trial in obesity.</div><div class="mfn-body">In summary, the preclinical obesity studies showed no effect on body weight. However, as exposure data are not yet finalized, it is currently not possible to conclude whether the outcome is driven by limited efficacy or insufficient systemic drug exposure following the formulation change. Against this backdrop, the decision to nevertheless proceed with preparations for a clinical application together with a new CRO represents a clear strategic choice, whereby the path toward clinical development continues, while the risk profile increases if the final preclinical results later indicate limited efficacy in the study. In light of the above, we will await complete preclinical study data before making eventual updates to our financial forecasts for Pila Pharma.<hr><a rel="noopener" href="https://analystgroup.se/kommentarer/kommentar-pa-pila-pharmas-preklinska-studieresultat-inom-obesitas-samt-signering-av-ett-avtal-med-en-ny-cro-avseende-kliniska-studier/">Read Analyst Group’s comment here</a><hr>About Analyst Group:&nbsp;One of Sweden's leading equity research&nbsp;boutiques with focus on small and medium-sized listed companies. <a rel="noopener" href="https://www.analystgroup.se/om-oss/">Read more about Analyst Group</a> &nbsp; This is a press release from Analyst Group regarding the publication of a comment on Pila Pharma. Readers may assume that Analyst Group has received compensation for making the comment. The Company has not been given an opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation or anything else that could be considered a subjective assessment.</div>

Analyst Group: Analyst Group Comment on Pila Pharma Initiated Preclinical Studies in Obesity